Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 260 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma May 23, 2023 Promising Signal of Efficacy for Adjuvant Nivolumab in Patients with Completely... July 19, 2023 Potential for Larger Gene Panels to Increase the Number of Molecularly... April 22, 2025 When Both Tumour-Infiltrating Lymphocytes and Gene Expression are Available, the Prognostic... January 23, 2023 Load more HOT NEWS Coping With the Holidays During COVID-19 and Cancer The Impact of COVID-19 on Black and Hispanic People with Cancer:... RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and... EMA Recommends Extending Indications for Zanubrutinib to Include Treatment of Patients...
